Category
blog
-
2023
-
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China
-
Despite FDA doubts, advisors back first-line Polivy use
-
FDA Approves Pfizer’s Zavzpret in Acute Treatment of Migraine
-
Solanezumab Fails to Halt Amyloid and Cognitive Decline in Preclinical Alzheimer’s
-
US FDA approves Acadia Pharmaceuticals’ Rett syndrome therapy
-
Gilead Awarded $175.2 Million Over HIV Drug Fraud Scheme
-
FDA Will Retain Some Guidances After End to COVID Emergency
-
Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 as a Potential Treatment for Duchenne Muscular Dystrophy
-
Ellipses Pharma’s Acute Myeloid Leukemia Candidate Gets Orphan Drug Nod
-
Sanofi to Acquire Provention Bio